Groowe Groowe / Newsroom / ANNX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ANNX News

Annexon, Inc. Common Stock

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

globenewswire.com
ANNX

Form 8-K

sec.gov
ANNX

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

globenewswire.com
ANNX

Form 8-K

sec.gov
ANNX

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

globenewswire.com
ANNX

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

globenewswire.com
ANNX

Form 8-K

sec.gov
ANNX

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

globenewswire.com
ANNX

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com
ANNX

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

globenewswire.com
ANNX